Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials

Andrés M. Arias-Lorza,James R. Costello,Sunil R. Hingorani,Daniel D. Von Hoff,Ronald L. Korn,Natarajan Raghunand

DOI: https://doi.org/10.1038/s41598-024-62470-9

IF: 4.6

2024-05-23

Scientific Reports

Abstract:Pre-clinical and clinical studies have shown that PEGPH20 depletes intratumoral hyaluronic acid (HA), which is linked to high interstitial fluid pressures and poor distribution of chemotherapies. 29 patients with metastatic advanced solid tumors received quantitative magnetic resonance imaging (qMRI) in 3 prospective clinical trials of PEGPH20: HALO-109-101 (NCT00834704), HALO-109-102 (NCT01170897), and HALO-109-201 (NCT01453153). Apparent Diffusion Coefficient of water (ADC), T1, k trans , v p , v e , and iAUC maps were computed from qMRI acquired at baseline and ≥ 1 time point post-PEGPH20. Tumor ADC and T1 decreased, while iAUC, k trans , v p , and v e increased, on day 1 post-PEGPH20 relative to baseline values. This is consistent with HA depletion leading to a decrease in tumor extracellular water content and an increase in perfusion, permeability, extracellular matrix space, and vascularity. Baseline parameter values predictive of pharmacodynamic responses were: ADC > 1.46 × 10 −3 mm 2 /s (Balanced Accuracy (BA) = 72%, p 0.54 s (BA = 82%, p < 0.01), iAUC < 9.2 mM-s (BA = 76%, p < 0.05), k trans < 0.07 min −1 (BA = 72%, p = 0.2), v e < 0.17 (BA = 68%, p < 0.01), and v p < 0.02 (BA = 60%, p < 0.01). A low v e at baseline was moderately predictive of response in any parameter (BA = 65.6%, p < 0.01 averaged across patients). These qMRI biomarkers are potentially useful for guiding patient pre-selection and post-treatment follow-up in future clinical studies of PEGPH20 and other tumor stroma-modifying anti-cancer therapies.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to use quantitative magnetic resonance imaging (qMRI) technology to evaluate the response of tumors to hyaluronidase (PEGPH20) treatment and explore the potential applications of these imaging biomarkers in patient selection and treatment monitoring.

### Background and Problems
1. **The Role of Hyaluronic Acid (HA) in Tumors**
- The tumor extracellular matrix (ECM) often contains a large amount of hyaluronic acid (HA), which is a linear polysaccharide. Each disaccharide unit can bind up to 15 water molecules, forming a viscoelastic gel - liquid phase with high interstitial fluid pressure (IFP).
- High IFP and dense ECM lead to tumor microvascular dysfunction, making it difficult for systemically administered chemotherapy drugs to be effectively distributed to tumor tissues.
- High levels of HA may also lead to a hypoxic and acidic environment within the tumor, further worsening the prognosis.

2. **The Mechanism of Action of PEGPH20**
- PEGPH20 is an experimental anticancer drug designed to target and degrade HA in tumors.
- In vitro and pre - clinical studies have shown that PEGPH20 can reduce HA in tumors, decrease IFP, increase perfusion, reduce water content, increase microvascular area, reduce hypoxia, increase pH, and change water diffusion, etc.

3. **Results of Clinical Trials**
- Early clinical trials have shown that PEGPH20 can reduce HA in tumors, increase perfusion, and prolong survival, especially in patients with high - HA tumors.
- However, the results of phase III clinical trials showed that although PEGPH20 increased the objective response rate (ORR), it failed to improve survival or progression - free survival (PFS).

### Research Objectives
1. **Evaluate Tumor Response After PEGPH20 Treatment**
- Through quantitative magnetic resonance imaging (qMRI) technology, evaluate the changes in multiple parameters of tumors after PEGPH20 treatment, including the apparent diffusion coefficient (ADC), T1 relaxation time, vascular permeability (ktrans), plasma volume fraction (vp), extracellular space volume fraction (ve), and the area under the gadolinium concentration curve (iAUC).

2. **Explore the Predictive Value of Imaging Biomarkers**
- Determine whether baseline parameter values can predict the pharmacological response of PEGPH20, thereby guiding the pre - selection of patients and follow - up after treatment.

### Methods
1. **Clinical and MRI Study Design**
- Collected MRI data from three early clinical trials (HALO - 109 - 101, HALO - 109 - 102, HALO - 109 - 201).
- Patients in each trial underwent qMRI scans at baseline and at least one time point after PEGPH20 treatment.

2. **Image Processing**
- Calculate ADC, T1, ktrans, vp, ve, and iAUC maps.
- Register the images and calculate parameters to ensure data consistency and accuracy.

3. **Statistical Analysis**
- Evaluate the significant differences before and after treatment by calculating the median parameter change for each tumor.
- Use the repeatability coefficient (RC) to determine the significance of parameter changes.

### Results
1. **Parameter Changes After Treatment**
- After PEGPH20 treatment, the ADC and T1 of the tumor decreased significantly on day 1, while iAUC, ktrans, vp, and ve increased significantly.
- These changes are consistent with the decrease in extracellular water content in the tumor due to HA degradation and the increase in perfusion, permeability, extracellular matrix space, and vascularity.

2. **Predictive Value of Baseline Parameters**
- Baseline parameter values can predict the pharmacological response of PEGPH20, for example:
- Baseline ADC > 1.46 × 10^(-3) mm²/s (balanced accuracy BA = 72%)
- Baseline T1 > 0.54 s (BA = 82%)
- Baseline iAUC < 9.2 mM - s (BA = 76%)
- Baseline ktrans < 0.07 min^(-1) (BA = 72%, p = 0.2)
- Baseline ve < 0.17 (BA = 68%)
- Baseline vp < 0